Ticker Symbol | Entity Name | Employer Id | As Of Date | Profile Url | Name | Website | Company Type | Industry | Active Status | Employer Status | Headquarters City | Year Founded | Rating: Overall | Rating: CEO (%) | Rating: Business Outlook (%) | Rating: Recommend (%) | Rating: Compensation & Benefits | Rating: Culture & Values | Rating: Career Opportunities | Rating: Diversity and Inclusion | Rating: Work/Life Balance | Rating: Senior Management | Ratings Star 1 Count | Ratings Star 2 Count | Ratings Star 3 Count | Ratings Star 4 Count | Ratings Star 5 Count | Ratings Count | Ratings Diversity and Inclusion Count | Ratings CEO Count | Ratings Star 1 (%) | Ratings Star 2 (%) | Ratings Star 3 (%) | Ratings Star 4 (%) | Ratings Star 5 (%) | Awards Count | Job Count | Review Count | Interview Experience: Positive | Interview Experience: Neutral | Interview Experience: Negative | Interview Channel: Online (%) | Interview Channel: Campus Recruiting | Interview Channel: Recruiter | Interview Channel: Employee Referral | Interview Channel: Staffing Agency | Interview Channel: In-Person | Interview Channel: Other | CEO Profile Image | CEO | Date Added | Date Updated | Company Name | Sector | Industry | CEO Gender | CEO Ethnicity |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
nyse:mrk | https://www.glassdoor.com?employer_id=438 | 438 | Apr 28th, 2024 12:00AM | Open | Merck | Open | Company - Public | Biotech & Pharmaceuticals | Rahway, NJ | 1891 | 4.10 | 86% | 79% | 85% | 4.00 | 4.00 | 3.80 | 4.20 | 3.90 | 3.60 | 38.00 | 78.00 | 213.00 | 522.00 | 744.00 | 1595 | 1665 | 704.00 | 2.382% | 4.89% | 13.354% | 32.727% | 46.646% | 24.00 | 7000 | 0.68 | 0.18 | 0.14 | 0.58 | 0.08 | 0.12 | 0.04 | 0.04 | 0.03 | Open | Rob Davis | Apr 28th, 2024 04:43PM | Apr 28th, 2024 04:43PM | Merck | Health Care | Pharmaceuticals & Biotechnology | ||||||
nyse:mrk | https://www.glassdoor.com?employer_id=363371 | 363371 | Apr 28th, 2024 12:00AM | Open | Immune Design | Open | Company - Public | Biotech & Pharmaceuticals | Seattle, WA | 5.00 | -100% | -100% | -100% | 4.00 | 4.00 | 4.00 | -1.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | Apr 28th, 2024 04:43PM | Apr 28th, 2024 04:43PM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=445 | 445 | Apr 28th, 2024 12:00AM | Open | EMD Millipore | Open | Subsidiary or Business Segment | Biotech & Pharmaceuticals | Boston, MA | 1668 | -0.10 | -10% | -10% | -10% | -0.10 | -0.10 | -0.10 | -0.10 | -0.10 | -0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Open | David Hutchinson | Apr 28th, 2024 04:43PM | Apr 28th, 2024 04:43PM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=14967 | 14967 | Apr 28th, 2024 12:00AM | Open | Idenix Pharmaceuticals | Open | Company - Public | Biotech & Pharmaceuticals | Cambridge, MA | 2003 | 3.00 | 100% | 0% | 31% | 3.20 | 3.00 | 2.50 | -1.00 | 3.90 | 2.70 | 0.00 | 0.00 | 1.00 | 0.00 | 321.00 | 6.00 | 1.00 | 1.00 | Ronald C. Renaud Jr. | Apr 28th, 2024 04:43PM | Apr 28th, 2024 04:43PM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=438 | 438 | Apr 26th, 2024 12:00AM | Open | Merck | Open | Company - Public | Biotech & Pharmaceuticals | Rahway, NJ | 1891 | 4.10 | 86% | 79% | 85% | 4.00 | 4.00 | 3.80 | 4.20 | 3.90 | 3.60 | 38.00 | 78.00 | 215.00 | 522.00 | 743.00 | 1596 | 1665 | 704.00 | 2.381% | 4.887% | 13.471% | 32.707% | 46.554% | 24.00 | 6995 | 0.68 | 0.18 | 0.14 | 0.58 | 0.08 | 0.12 | 0.04 | 0.04 | 0.03 | Open | Rob Davis | Apr 26th, 2024 08:29AM | Apr 26th, 2024 08:29AM | Merck | Health Care | Pharmaceuticals & Biotechnology | ||||||
nyse:mrk | https://www.glassdoor.com?employer_id=14967 | 14967 | Apr 26th, 2024 12:00AM | Open | Idenix Pharmaceuticals | Open | Company - Public | Biotech & Pharmaceuticals | Cambridge, MA | 2003 | 3.00 | 100% | 0% | 31% | 3.20 | 3.00 | 2.50 | -1.00 | 3.90 | 2.70 | 0.00 | 0.00 | 1.00 | 0.00 | 325.00 | 6.00 | 1.00 | 1.00 | Ronald C. Renaud Jr. | Apr 26th, 2024 08:29AM | Apr 26th, 2024 08:29AM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=363371 | 363371 | Apr 26th, 2024 12:00AM | Open | Immune Design | Open | Company - Public | Biotech & Pharmaceuticals | Seattle, WA | 5.00 | -100% | -100% | -100% | 4.00 | 4.00 | 4.00 | -1.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | Apr 26th, 2024 08:29AM | Apr 26th, 2024 08:29AM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=445 | 445 | Apr 26th, 2024 12:00AM | Open | EMD Millipore | Open | Subsidiary or Business Segment | Biotech & Pharmaceuticals | Boston, MA | 1668 | -0.10 | -10% | -10% | -10% | -0.10 | -0.10 | -0.10 | -0.10 | -0.10 | -0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Open | David Hutchinson | Apr 26th, 2024 08:29AM | Apr 26th, 2024 08:29AM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=14967 | 14967 | Apr 25th, 2024 12:00AM | Open | Idenix Pharmaceuticals | Open | Company - Public | Biotech & Pharmaceuticals | Cambridge, MA | 2003 | 3.00 | 100% | 0% | 31% | 3.20 | 3.00 | 2.50 | -1.00 | 3.90 | 2.70 | 0.00 | 0.00 | 1.00 | 0.00 | 323.00 | 6.00 | 1.00 | 1.00 | Ronald C. Renaud Jr. | Apr 25th, 2024 06:51PM | Apr 25th, 2024 06:51PM | Merck | Health Care | Pharmaceuticals & Biotechnology | |||||||||||||||||||||||
nyse:mrk | https://www.glassdoor.com?employer_id=363371 | 363371 | Apr 25th, 2024 12:00AM | Open | Immune Design | Open | Company - Public | Biotech & Pharmaceuticals | Seattle, WA | 5.00 | -100% | -100% | -100% | 4.00 | 4.00 | 4.00 | -1.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | Apr 25th, 2024 06:51PM | Apr 25th, 2024 06:51PM | Merck | Health Care | Pharmaceuticals & Biotechnology |